Nanoform Finland Oyj Gestione

Gestione criteri di controllo 2/4

Nanoform Finland Oyj Il CEO è Edward Haeggstrom, nominato in Jan2015, ha un mandato di 9.75 anni. possiede direttamente 6.32% delle azioni della società, per un valore di € 7.49M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 5.8 anni e 5.3 anni.

Informazioni chiave

Edward Haeggstrom

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	9.8yrs
Proprietà del CEO	6.3%
Durata media del management	5.8yrs
Durata media del Consiglio di amministrazione	5.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

Companies Like Nanoform Finland Oyj (HEL:NANOFH) Are In A Position To Invest In Growth

Jan 25

What You Need To Know About Nanoform Finland Oyj's (HEL:NANOFH) Investor Composition

Dec 21

AMMINISTRATORE DELEGATO

Edward Haeggstrom (55 yo)

9.8yrs

Mandato

Prof. Edward Olof Haeggstrom is a Co-Founder of Nanoform Finland Oy and has been its Chief Executive Officer since 2015. Prof. Haeggstrom is Scientific Advisor and the Chairman of the Board of Directors of...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Albert Haeggstrom	CFO & Director	6.8yrs	€80.37k	0.83% € 981.3k
Edward Haeggstrom	Co-Founder & CEO	9.8yrs	Nessun dato	6.32% € 7.5m
Henri von Haartman	Director of Investor Relations	no data	Nessun dato	Nessun dato
Peter Hanninen	General Counsel & Chief Development Officer	4.1yrs	Nessun dato	0.12% € 142.7k
David Rowe	Head of Manufacturing	5.8yrs	Nessun dato	Nessun dato
Christian Jones	Chief Commercial Officer	6.8yrs	Nessun dato	0.45% € 531.5k
Antonio Da Silva	Chief of Business Operations	1.8yrs	Nessun dato	0.029% € 33.9k
Johanna Kause	Chief Quality Officer	1.1yrs	Nessun dato	Nessun dato
Jamie Unwin	Vice President of Strategic Insight	no data	Nessun dato	Nessun dato

5.8yrs

Durata media

53yo

Età media

Gestione esperta: Il team dirigenziale di NANOFH è esperto e expertise (durata media dell'incarico 5.8 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Albert Haeggstrom	CFO & Director	9.8yrs	€80.37k	0.83% € 981.3k
Miguel Calado	Independent Chairman of the Board	5.6yrs	€94.50k	0.076% € 89.7k
Jeanne Thoma	Independent Director	2.9yrs	€58.51k	0.026% € 31.0k
Mads Laustsen	Independent Vice Chairman of the Board	5.1yrs	€58.51k	0.026% € 31.0k

5.3yrs

Durata media

66yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di NANOFH sono considerati esperti (durata media dell'incarico 5.3 anni).

Nanoform Finland Oyj Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Nanoform Finland Oyj CTO Niklas Sandler Transitions to Technology Advisor to the CEO, effective, January 1, 2023

Nanoform Finland Oyj, Annual General Meeting, Apr 12, 2023

Nanoform's Gonçalo Andrade Steps Down as Chief of Business Operations

Recent updates

Price target decreased by 9.1% to €4.00

Second quarter 2024 earnings: EPS in line with expectations, revenues disappoint

First quarter 2024 earnings released: €0.09 loss per share (vs €0.06 loss in 1Q 2023)

New minor risk - Shareholder dilution

Nanoform Finland Oyj has filed a Follow-on Equity Offering.

Consensus revenue estimates decrease by 21%, EPS upgraded

No longer forecast to breakeven

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

New minor risk - Profitability

Nanoform Finland plc Receives Positive Results from its Own Pre- Clinical, In-Vivo Study of a Nanocrystalline-Enabled Apalutamide Oral Formulation

New major risk - Share price stability

Nanoform Announces Important Milestone with Promising Clinical Results for Patient-Centric Nanotechnology-Enhanced Enzalutamide

Nanoform Finland plc Commences Relative Bioavailability Study of Nanotechnology-Enhanced Enzalutamide

Forecast to breakeven in 2026

Nanoform Finland Oyj to Report Nine Months, 2024 Results on Nov 22, 2024

Consensus revenue estimates fall by 31%

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

We Think Nanoform Finland Oyj (HEL:NANOFH) Can Afford To Drive Business Growth

Consensus revenue estimates fall by 31%

No longer forecast to breakeven

Price target decreased by 16% to €6.00

Consensus revenue estimates decrease by 18%

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Finnish Medicines Agency Renews Nanoform's GMP License and Nanoform Starts Clinical API Manufacturing of Blockbuster Medicine Candidate

We're Not Very Worried About Nanoform Finland Oyj's (HEL:NANOFH) Cash Burn Rate

Consensus revenue estimates fall by 37%

Price target decreased by 9.6% to €8.28

Forecast to breakeven in 2025

Nanoform Finland Oyj CTO Niklas Sandler Transitions to Technology Advisor to the CEO, effective, January 1, 2023

Nanoform Finland Oyj to Report Q3, 2023 Results on Nov 22, 2023

Nanoform Finland Oyj, Annual General Meeting, Apr 12, 2023

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

We're Hopeful That Nanoform Finland Oyj (HEL:NANOFH) Will Use Its Cash Wisely

Consensus revenue estimates fall by 29%

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Nanoform's Gonçalo Andrade Steps Down as Chief of Business Operations

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Nanoform Finland Plc. Launches "STARMAP® Online" Placing AI-Power at the Fingertips of Medicine Developers

Nanoform Finland Plc. Launches "STARMAP® Online" Placing AI-Power at the Fingertips of Medicine Developers

Consensus forecasts updated

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Nanoform signs GMP manufacturing program with TargTex following formulation success

Companies Like Nanoform Finland Oyj (HEL:NANOFH) Are In A Position To Invest In Growth

Consensus revenue estimates fall to €2.05m

Third quarter 2021 earnings: EPS and revenues miss analyst expectations

Nanoform technology delivers successful results for Herantis CDNF drug candidate

Second quarter 2021 earnings released: €0.07 loss per share (vs €0.14 loss in 2Q 2020)

First quarter 2021 earnings released: €0.06 loss per share (vs €0.12 loss in 1Q 2020)

Director has left the company

Nanoform Announces Completion and Final Results of Clinical Study

Nanoform Finland Oyj has completed a Follow-on Equity Offering in the amount of €40.000001 million.

Nanoform Finland Oyj to Report Q1, 2021 Results on May 27, 2021

Nanoform Finland Announces Further Positive Interim Results from Its Ongoing Clinical Study

New 90-day high: €7.73

New 90-day high: €7.40

Nanoform's Clinical Study Indicates Positive Interim Results

Nanoform Finland plc Announces First Dosing of Nanoformed Drug Successfully Accomplished

What You Need To Know About Nanoform Finland Oyj's (HEL:NANOFH) Investor Composition

Herantis Pharma Plc and Nanoform Finland Plc Signs Letter of Intent for Collaboration

New 90-day high: €4.59

Nanoform Launches Technology for Biologics and Sets New Near-Term Business Target for 2021

Nanoform Finland Oyj to Report Q3, 2020 Results on Nov 27, 2020

New 90-day low: €3.91

First half earnings released

AMMINISTRATORE DELEGATO

Mandato

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media